CK34βE12、CK5/6、P63、P504s在前列腺良恶性病变中的表达、统计分析及意义  

Expression of CK34βE12,CK5/6,P63,p504s in benign and malignant lesions of prostate,statistical analysis and significance

作　　者：颜赟坤 柳建军 陈浩栋 何光阳 李健维 YAN Yunkun;LIU Jianjun;CHEN Haodong;HE Guangyang;LI Jianwei(Department of Urology,Affiliated Hospital of Guangdong Medical University,Zhanjiang,Guangdong,524000,China;Department of Urology,Leizhou People's Hospital,Zhanjiang,Guangdong,524200,China)

机构地区：[1]广东医科大学附属医院泌尿外科,广东湛江524000 [2]雷州市人民医院泌尿外科,广东湛江524200

出　　处：《当代医学》2021年第22期64-67,共4页Contemporary Medicine

基　　金：湛江市科技计划项目(2018B01134)。

摘　　要：目的探究CK34βE12、CK5/6、P63及P504s四项指标在前列腺良恶性病变中的表达及临床意义。方法选取2013年1月至2018年3月本院收治的60例前列腺手术切除及穿刺活检的标本,随机分为前列腺恶性病变组(n=40)和前列腺良性病变组(n=20),恶性前列腺病变组采用Gleason评分标准进一步分为低危组(n=15)、中危组(n=15)和高危组(n=10);良性前列腺病变组分为腺体完全性萎缩组(n=15)和腺体部分性萎缩组(n=5)。采用免疫组织化学法检测组织CK34βE12、CK5/6、P63及P504s的表达情况,分析CK34βE12、CK5/6、P63及P504s这4项指标在前列腺良恶性病变中的表达情况。结果CK34βE12在恶性前列腺病变组中呈低表达,而在良性前列腺病变组中呈高表达;CK5/6在恶性前列腺病变组中呈低表达,而在良性前列腺病变组中呈高表达;P63在恶性前列腺病变组中呈低表达,而在良性前列腺病变组中呈高表达;P504s在恶性前列腺病变组中呈高表达,而在良性前列腺病变组中呈低表达;两组CK34βE12、CK5/6、P63以及P504s表达情况比较差异有统计学意义(P<0.05)。低危组、中危组、高危组P504s表达强度比较差异有统计学意义(P<0.05);低危组表达强度明显低于高危组和中危组(P<0.05),但中危组和高危组P504s表达强度比较差异无统计学意义。腺体部分性萎缩组和腺体完全性萎缩组CK34βE12、CK5/6以及P63表达强度比较差异无统计学意义。腺体部分性萎缩组中部分样本不表达CK34βE12和CK5/6;腺体完全性萎缩组中,部分样本不表达CK5/6。结论CK34βE12、CK5/6、P63以及P504s联合检测在前列腺癌和良性病变的鉴别诊断中有良好的应用价值。Objective To explore the expression and clinical significance of CK34βE12,CK5/6,P63 and P504s in prostate benign and malignant lesions.Methods From January 2013 to March 2018,60 cases of prostate surgical resection and needle biopsy specimens were selected and they were randomly divided into prostate malignant disease group(n=40)and prostate benign disease group(n=20).The prostate malignant disease group was further divided into low-risk group(n=15),intermediate-risk group(n=15)and high-risk group(n=10)according to the Gleason scoring stan-dard;the prostate benign disease group was divided into gland atrophy sexual atrophy group(n=15)and partial glandular atrophy group(n=5)accord-ing to complete gland.Immunohistochemistry was used to detect the expression of CK34βE12,CK5/6,P63 and P504s in tissues,and the expression of CK34βE12,CK5/6,P63 and P504s in prostate benign and malignant lesions were analyzed.Results CK34βE12 showed low expression in the prostate malignant disease group,but high expression in the prostate benign disease group;CK5/6 showed low expression in the prostate malignant disease group and high expression in the prostate benign disease group;P63 was showed low expression in the prostate malignant disease group,but high expression in the prostate benign disease group;P504s showed high expression in the prostate malignant disease group,but low expression in the prostate benign disease group;there were significant differences in the expression of CK34βE12,CK5/6,P63 and P504s between the two groups(P<0.05);the expression intensity of P504s among the low-risk group,intermediate-risk group,and the high-risk group was significantly difference(P<0.05);the expression intensity of the low-risk group was significantly lower than that of the high-risk group and the intermediate-risk group(P<0.05),but there was no significant difference in the expression intensity of P504s between the intermediate-risk group and the high-risk group.There was no significant difference in the expression intensity of CK34βE

关 键 词：前列腺癌 前列腺增生 诊断 CK34ΒE12 CK5/6 P63 P504S 

分 类 号：R737.25[医药卫生—肿瘤]